Abzena and Mabqi have announced a partnership integrating antibody discovery capabilities with development and manufacturing ...

Though the FDA has requested no new data, the additional information reflects a major amendment to Rhythm’s supplemental new ...

Approval of J&J's Darzalex marks a milestone for high-risk sMM patients, but GlobalData analyst Biswajit Podder believes ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the MHRA for all four formulations of ...

Cencora is set to invest $1bn by 2030 to expand its US pharmaceutical distribution network, adding resilience and capacity.

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

Both companies have upped their offers for Metsera amid a bidding war, but Novo Nordisk comes armed with an extra $1.9bn.

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...

The guidance change marks the latest adjustment Novo has made to its 2025 outlook as the company battles a changing market.

The US Food and Drug Administration (FDA) has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat genetic ...